MedTrace Logo

EO4010 in Previously Treated Metastatic Colorectal Carcinoma

NCT05589597 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-08-22

No results posted yet for this study

Summary

Open-label multicenter study

Conditions

  • Colorectal Cancer Metastatic

Interventions

DRUG

EO4010

Sequential assignment

Sponsors & Collaborators

  • Enterome

    lead INDUSTRY

Principal Investigators

  • Jan Fagerberg · Enterome

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2025-05-30
Completion
2025-05-30
FDA Drug
Yes

Countries

  • United States
  • France
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05589597 on ClinicalTrials.gov